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Abstract The vascular endothelium and shear stress are critical
determinants of physiological hemostasis and platelet function
in vivo, yet current diagnostic and monitoring devices do not
fully incorporate endothelial function under flow in their assess-
ment and, therefore, they can be unreliable and inaccurate. It is
challenging to include the endothelium in assays for clinical
laboratories or point-of-care settings because living cell cultures
are not sufficiently robust. Here, we describe a microfluidic de-
vice that is lined by a human endothelium that is chemically
fixed, but still retains its ability to modulate hemostasis under
continuous flow in vitro even after few days of storage. This
device lined with a fixed endothelium supports formation of
platelet-rich thrombi in the presence of physiological shear, sim-
ilar to a living arterial vessel. We demonstrate the potential clin-
ical value of this device by showing that thrombus formation and
platelet function can be measured within minutes using a small
volume (0.5 mL) of whole blood taken from subjects receiving
antiplatelet medications. The inclusion of a fixed endothelial
microvessel will lead to biomimetic analytical devices that can
potentially be used for diagnostics and point-of-care applications.
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1 Introduction
Mutual signaling between vascular endothelium and platelets
is critical for regulation of haemostasis and thrombotic disor-
ders associated with various diseases. (Alexandru et al. 2012;
Lowenberg et al. 2010; Siddiqui et al. 2013; Wu and
Thiagarajan 1996) Yet no practical diagnostic assays exist that
can measure cross-talk between platelets and inflamed vessel
walls in the presence of physiological shear. Over the last
decade, microfluidic devices that contain hollow channels
lined by living endothelium have been exposed to flowing
blood to study the basic science of thrombosis in vitro
(Colace et al. 2013; Neeves et al. 2013; Tsai et al. 2012;
Zheng et al. 2012). While these devices are useful for advanc-
ing research, they are not used in practical or clinical settings
because living cell cultures are not robust and the devices can
not be stored for extended times. The rare microfluidic devices
that have been used in diagnostic settings are typically lined
with collagen to mimic thrombus formation and platelet ag-
gregation induced in response to vascular wall injury. While
more relevant than coagulation assays carried out in solution,
these devices still fail to capture the dynamic physiological
interplay between endothelial cells, platelets and fluid shear
stress that are critical for control of blood clotting in inflam-
matory diseases (Branchford et al. 2015; Neeves et al. 2013).
The aim of this study was to explore whether a microfluidic
device lined by a chemically preserved (fixed) human endo-
thelium will retain its ability to support thrombus formation
and platelet adhesion when human whole blood is flowed
through the channel at an arterial shear rate. If this were pos-
sible, it could provide a way to create more robust devices for
analysis of haemostasis and thrombosis under more physio-
logically relevant conditions in clinical laboratories and point-
of-care settings in the future. Here, we demonstrate that
microfluidic devices lined by fixed human endothelium can
be used in this manner, and we demonstrate its physiological
relevance by comparing results obtained from analysis of
blood samples from human patients taking antiplatelet medi-
cation with results obtained using standard aggregometry or
similar collagen-coated microfluidic devices.
2 Materials and methods
Microfluidic device design and fabrication The
microfluidic device was designed using AutoCAD software,
master templates were fabricated by photolithography on Si
(100) wafers (University Wafer Corp.) and soft lithography
was used to prepare the devices with polydimethylsiloxane
(PDMS) (Duffy et al. 1998). We placed six independent
microchannels (each 400 μm wide, 100 μm high, 2 cm long)
on the PDMS block with the dimensions of a standard glass
slide (75 × 25 mm). The inlet well was cut to a size of 3.5 mm
with a punch (Harris Uni Core) in order to fit an open slip-tip
syringe head (BD Biosciences) that was used as a blood res-
ervoir. The outlet was punched to a size of 1 mm. A 1/16″
female barbed luer connector was inserted in the outlet and
1/16″ ID medical grade tygon tubing (Formula: ND-100-05)
of 35 cm was inserted in this connector. The other end of the
tubing was connected to a 3 mL syringe that was fitted to a
syringe pump (Harvard Apparatus, PhD Ultra).
Microchannel functionalization, endothelial culture, fixa-
tion and fluorescent staining The microfluidic devices were
exposed to oxygen plasma for 30 s, at a power of 50 W, using
a PE-100 plasma sterilizer (Plasma Etch, Inc. NV, USA) and
then treated with 1 % (3-aminopropyl)-trimethoxysilane
(APTMS; Sigma) in 100 % anhydrous ethanol, for 10 min.
After subsequent rinsing with 70 % ethanol and 100 % etha-
nol, the devices were baked at 80 °C for 2 h. Then, the inside
of the channels was coated with rat type I collagen (100 μg/
mL; Corning) overnight at 37 °C in a 5 % CO2 incubator,
followed by rinsing with Endothelial Growth Medium-2
(EGM-2; Lonza). To line all four sides of the rectangular
channel with endothelium, human umbilical vein endothelial
cells (HUVECs; mixed donor; 1.25 × 107/mL; Lonza) were
first flowed into the collagen-coated microchannels. Then, the
devices were incubated for 20 min while upside down, after
which a fresh HUVEC suspensionwas introduced in the chan-
nels and incubated for eight additional hours to promote cell
attachment and spreading on all surfaces of the channel. The
channels were then rinsed with EGM-2, with or without
TNF-α (recombinant from E. coli, Sigma). After incubating
for up to 18 h, a 4 % formaldehyde solution (Sigma) was
flushed through the channels and the devices were incubated
for 15 min at room temperature. Finally, the devices were
rinsed twice with EGM-2 and then placed at 4 °C for upto
36 h before use. Mouse or rabbit antibodies against intercel-
lular adhesion molecule-1 (ICAM-1), vascular adhesion
molecule-1 (VCAM-1), tissue factor (TF, Santa Cruz), von
Willebrand Factor (VWF, Abcam) and Vascular Endothelial-
Cadherin (VE-Cadherin, Santa Cruz) were perfused into the
device, incubated for 3 h, washed, and visualized with a goat-
anti-mouse or anti-rabbit fluorescent IgG (Invitrogen) incubat-
ed for 3 h.
Blood samples and human subjectsHuman blood (Research
Blood Components, Cambridge, MA), acquired in 3.2 % so-
dium citrate tubes was used within 5 h of blood draw, to
prevent pre-analytical effects on platelet function. (Cattaneo
et al. 2009). Institutional review board (IRB) approval was
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obtained for use of discarded blood samples. Subjects were
selected from among patients who were taking antiplatelet
medication. A total of 11 samples were used for analysis; of
these, 8 subjects were on aspirin alone and 3 were on aspirin
and clopidogrel (Plavix).
Blood perfusion The inlet reservoir of the microfluidic device
was filled with whole blood (500 μL), containing platelets
labeled with human CD41-PE antibody (10 μL/mL blood,
10 min incubation, Invitrogen), and sometimes containing
fluorescently labeled fibrinogen (10 μg/mL; Life Sciences).
Blood was pulled through the device (30 μL/min) via the
syringe pump, resulting in an arteriole-like shear rate of
750 s−1 (Papaioannou and Stefanadis 2005). After 2 min,
100 mM calcium (CaCl2) and 75 mM magnesium (MgCl2)
were added to the blood in the reservoir (1: 10 ratio) to restore
coagulation-activated blood clotting (Jain et al. 2016; Neeves
et al. 2014).
Image acquisition and analysis Platelets were visualized
using time-lapse fluorescence imaging (20×, NA 0.4), and a
time series of a 10-frame panorama (6 mm long × 0.665 mm
wide) of the microchannel was recorded every 30 s.
Measurements were made near the center of the device, close
to 1 cm downstream of the blood flow inlet. The maximum
intensity of the resulting image stack was projected along
time, thresholded, segmented and cropped to the central
200 μm of the channel width for analysis. Platelet coverage
was computed from the binary image as the ratio of bright
pixels to the total number of pixels in the image.
Light transmission aggregometry (LTA) Blood samples
were centrifuged at 290 g for 10 min (no brake applied) to
collect platelet-rich plasma (PRP). To obtain a reference solu-
tion for each sample, PRP was centrifuged at high speed to
pellet platelets (1000 g, 10 min) and collect platelet-poor plas-
ma (PPP). LTA was performed at 37 °C under magnetic stir-
ring using a Chrono-Log Corporation instrument and reagents
(ADP 10 μM and collagen 2 μg/mL).
Statistical analysisAll data are presented as mean ± standard
error (SEM). Two-tailed P values were obtained from the
statistical t-test or one way ANOVA using GraphPad Prism
V6.
3 Results and discussion
Formation and evaluation of microfluidic devicesWe used
soft lithography to fabricate a microfluidic device containing a
rectangular microchannel (400 μm wide, 100 μm high, 2 cm
long, Fig. 1a), with six similar channels on each chip (Fig. 1b).
The inner surface of all four walls of the microchannel were
coated with collagen prior to culturing HUVECs on this sur-
face to create a tube lined by a continuous, confluent endothe-
lial cell monolayer (Fig. 1c, d, Movie 1). Multiple endothelial
adhesion molecules are involved in the recruitment of blood
cells and platelets during thrombosis in vivo. (Sagripanti and
Carpi 2000) In previous studies, we showed that treatment of
living endothelium cultured in microfluidic channels with the
inflammatory cytokine TNF-α results in an increase in expres-
sion of surface adhesion molecules (e.g., ICAM-1, VCAM-1)
within 4 h after addition (Benam et al. 2016; Huh et al. 2010).
To explore whether a fixed endothelium would retain expres-
sion of surface molecules that could potentially exacerbate
inflammation and thrombosis, we pre-activated the endotheli-
um inside the device by adding increasing doses of TNF-α (0,
5, and 100 ng/mL) for approximately 18 h, and then fixed
them with paraformaldehyde, rinsed three times and stored
them at 4 °C in a humid environment. Interestingly, we found
that the fixed endothelium continued to exhibit a dose-
dependent increase in staining for ICAM-1 (Fig. 1e) and
VCAM-1 (Fig. 1f), as well as VWF (Fig. 1g) and tissue factor
(Fig. 1h), which mediate thrombus formation induced by
TNF-α by promoting adhesion of blood cells and platelets
(Sagripanti and Carpi 2000; Verhamme and Hoylaerts 2006;
Wu and Thiagarajan 1996).
Fibrin and platelet function analysis Next, we explored
whether the fixed endothelium that had been stored for 24–
36 h would retain its ability to promote haemostasis and
thrombus formation when we perfused recalcified citrated
whole blood through the device at an arterial shear rate of
750 s−1 (25 dyne/cm2), while analyzing platelet adhesion over
15 min of flow. When blood from a healthy donor was flowed
over a fixed quiescent endothelium, there was virtually no
platelet adhesion on the surface (Fig. 2a, b), consistent with
the low level of expression of vascular adhesion molecules
(Fig. 1e–h). In contrast, when devices were used with endo-
thelium that was pretreated with increasing doses of TNF-α
prior to fixation, a dose-dependent increase in platelet adhe-
sion to the surface of the fixed endothelium was observed
(Fig. 2a, b and Movie 2). Importantly, we did not observe
any significant difference in platelet adhesion when we com-
pared living versus chemopreserved endothelium, with or
without treatment with TNF-α (Fig. 2b). Thus, these findings
confirm that the fixed endothelium retains its pro-thrombotic
activity and supports physiologically relevant levels of
cytokine-induced platelet adhesion after fixation and storage.
Furthermore, when we perfused whole blood containing fluo-
rescently labeled fibrinogen, we found that the thrombi also
contained a significant amount of fibrin if the endothelium
was pre-treated with TNF-α before fixation (Fig. 2c), which
confirmed that the fixed endothelial surface also retains its
ability to activate the coagulation cascade. The morphology
and adhesion pattern (Movie 2) of these thrombi (shape of a
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teardrop containing a core and a surrounding shell) (Stalker
et al. 2014). Also was similar to that of clots formed on living
endothelium in vivo, (Cooley 2011; Falati et al. 2002) and sig-
nificantly different from those formed on bare collagen-coated
flow chambers (shape of long tethers) (Colace et al. 2011)
Taken together, these results demonstrate that the microfluidic
device lined by fixed human endothelium is capable of repro-
ducing physiologically relevant thrombus formation.
Analysis of antiplatelet therapy These findings inspired us
to investigate if the microfluidic device containing the fixed
endothelium could have potential value as a clinical diagnostic
device, and thus, we carried out preliminary studies to deter-
mine whether it can be used to detect antiplatelet drug effects
in healthy donors and patients taking antiplatelet medication.
We first perfused a microdevice containing fixed endothelium
that was pretreated with a physiologically relevant dose of
TNF-α (5 ng/mL) (Damas et al. 1989; Kim et al. 2014;
Schlitt et al. 2004) with whole blood from a healthy donor
containing 0 to 100 μg/mL (clinical range ~1–10 μg/mL)
(Mascelli et al. 1998) of the antiplatelet GP IIb/IIIa antagonist,
abciximab (ReoPro®). By applying widefield microscopy as a
quick and easy way to quantitate antiplatelet effects, we
observed dose-dependent inhibition of platelet adhesion to
the surface of the fixed endothelium, with optimal effects being
observed at 10 μg/mL or higher (Fig. 3a), which is consistent
with previous studies using flow cytometric analysis (Rossi
et al. 2001). In contrast, all concentrations of abciximab pro-
duced virtually complete inhibition of platelet aggregation (no
dose dependence) as detected using conventional LTA, regard-
less of whether adenosine diphosphate (ADP) or collagen was
used as an agonist (Fig. 3b). Moreover, while there appeared to
be a small suppressive effect on platelet adhesion when the
same blood samples were flowed through a collagen-coated
flow chamber without an endothelial cell layer, the differences
in platelet adhesion induced by different abciximab doses were
not statistically significant (Fig. 3c). Thus, the microfluidic
device containing the fixed endothelium provided a more ro-
bust measure of platelet function, with a higher dynamic re-
sponse across a range of abciximab concentrations than these
standard platelet function assays that are currently used in clin-
ical laboratories. Notably, these findings also indicate that the
fixed surface of the endothelium retains its ability to modulate
platelet interactions via the GPIIb/IIIa pathway that is involved
in multiple thrombotic and vascular processes, as this is the
target of abciximab (Bombeli et al. 1998).
Fig. 1 Engineering of the microfluidic device containing a chemically
preserved endothelium. a Schematic of the microfluidic device showing a
blood inlet reservoir, followed by the straight microchannel that ends at
the outlet, where the syringe pump is attached to pull the blood, and b a
photograph of a single polydimethylsiloxane (PDMS) microfluidic chip
containing six independent microfluidic devices (bar, 15 mm) fabricated
on a glass slide. c A fluorescence micrograph showing the entire
microchannel covered with human umbilical vein endothelial cells
(HUVECs) immunostained against the cell adhesion molecule, VE-
cadherin (bar, 1 mm). d Confocal immunofluorescence microscopic
images showing a section of the microchannel with HUVECs when
viewed from above (‘xy’) and reconstruction of cross-sectional views
from the front and the side (‘yz’ and ‘xz’, respectively) demonstrating
full coverage of all microfluidic channel walls. (bottom; green, VE-
Cadherin; blue, nuclear DAPI; bar, 200 μm). e–h Graph showing
fluorescence (normalized by the untreated endothelium) measured after
immunostaining the fixed endothelium with ICAM-1 (e), VCAM-1 (f),
VWF (g), or tissue factor (h). *P < 0.05 versus untreated; n = 3
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We then perfused whole blood isolated from human subjects
who are regular users of antiplatelet drugs through the
microfluidic device. As expected, patients taking antiplatelet
drugs showed a significant reduction in platelet aggregation
when tested using the device compared to healthy donors
(Fig. 3d).While similar results were obtained using conventional
LTA (Fig. 3e), our microfluidic assay did not require sample
preparation or use of exogenous agonists. Our assay also required
only 15min to complete compared to the longer time (~2 h) often
required for completion of the LTA assay. Most importantly,
platelet inhibition could not be reliably detected in these subjects
using a collagen-coated flow chamber, as therewas no significant
difference in platelet coverage between normal controls and pa-
tients receiving antiplatelet therapy in that assay (Fig. 3f). Taken
together, these findings suggest that our microfluidic device con-
taining fixed endothelium could potentially be applied as a plate-
let function test in clinical diagnostic laboratories aswell as point-
of-care settings in the future, although much more clinical vali-
dation is still clearly required.
4 Conclusion
Since the simple microfluidic devices described here contain
human endothelial cells that are chemically preserved by fix-
ation, they can be stored, shipped and usedwhenever required,
either in a laboratory setting or point-of-care settings. Our
demonstration that this shear-inclusive whole blood assay
can be used to evaluate platelet aggregation and inhibition
with drugs in patient blood samples provides the proof-of-
concept that this microfluidic device offers a way to detect
physiologically important contributions of the endothelium
and dynamic blood flow in the analysis of haemostasis and
thrombosis, which are neglected by currently available de-
vices. The fixed endothelium may have lost some of its live
in vivo functions (e.g., release of bioactive messengers like
nitric oxide), and the exact mechanism by which our surface
promotes platelet adhesion and thrombosis is most likely
multi-factorial and will require further characterization to un-
derstand. Also, the inflammation-led thrombus formation that
we see in our device is mechanistically distinct from platelet
aggregometry and collagen flow chamber studies and possibly
represents a more complex system that more faithfully repli-
cates in vivo conditions, relevant to blood coagulation and
platelet function. Correspondingly, our results suggest that in
the 15 min period during which we analyze blood flow, the
fixed normal (unstimulated) endothelium retains its ability to
prevent blood clotting, whereas when it is preactivated with
TNF-α prior to fixation, the endothelium effectively promotes
platelet adhesion and thrombosis in vitro. Importantly, evalu-
ation of this type of propensity for whole blood thrombus
formation in a diseased setting is not possible with
aggregometry or collagen chambers. While the simpler assays
may allow dissection of individual signaling components
(e.g., collagen activation pathways), the results obtained so
far with those assays correlate poorly with clinical outcomes
(Dahlen et al. 2012) likely because thrombosis associated with
most diseases is related more to inflammatory changes than to
wall injury. In contrast, our system that more closely mimics
Fig. 2 Platelet coverage and fibrin formation on the fixed endothelium in
the microdevice. a Representative maximum intensity projection
micrographs showing fluorescently labeled platelets adhering to the
fixed endothelium in a tumor necrosis factor (TNF-α) dose-dependent
manner (bar, 100 μm). b Graph showing platelet coverage when blood
is perfused inside the microchannel lined with a living or fixed
endothelium that was stimulated by TNF-α before fixation. Comparison
of living vs. fixedmicrochannels was not significantly different (P > 0.05)
at each TNF-α concentration. (n = 4; *P < 0.05). c Fluorescent
micrograph shows fibrin (green) is formed along with platelet aggregates
(red) on a fixed endothelium that was pretreated with TNF-α and
perfused with recalcified citrated whole blood (left, bar, 200 μm; right,
bar, 20 μm)
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in vivo pathophysiological conditions may be able to provide a
better indicator of patient risk for ischemic events.
Recently, thrombus formation and platelet adhesion have
been visualized when flowing blood contacts various homo-
geneous relevant molecular ligands in vitro, (de Witt et al.
2014) but none of these ligands induce formation of thrombi
with a morphology that mimic clots observed on the endothe-
lial surface in laser-induced vascular injury models in vivo
(Cooley 2011; Falati et al. 2002), whereas our assay is able
to reconstitute this response (Fig. 2a–c, Movie 2). Also, while
we only demonstrated retention of expression of four promi-
nent adhesive ligands (VWF, TF, ICAM-1 and VCAM-1) on
the surface of the fixed endothelium, additional adhesion mol-
ecules (e.g., other integrins) could also be present, which
could be explored in future mechanistic studies that are be-
yond this initial report describing the novel functional
capabilities of this microfluidic device-based haemostasis
and thrombosis assay. Nevertheless, our results show that this
simple assay permits qualitative and quantitative analysis of
pro-thrombotic and pro-coagulant responses of the fixed en-
dothelium, and that the results we observed closely mimic
those exhibited by living endothelium. Because we analyze
clot formation in cytokine-stimulated endothelium, the mea-
surements obtained using this device also might be more in-
dicative for thrombus formation on an inflamed endothelium
as might be found, for example, in an atherosclerotic plaque
(Neeves et al. 2014), than those obtained with conventional
hemostasis assays.
In this study, we cultured easily obtained HUVECs, but
similar studies can be carried out using endothelium derived
from primary cells or induced pluripotent (iPS) cells, which
opens up the possibility of developing patient-specific
Fig. 3 Assessment of antiplatelet therapy with the microfluidic device. a
Platelet coverage on the fixed endothelium pretreated with TNF-α when
blood samples containing different doses of the drug abciximab were
perfused through the microfluidic device (n = 4) b Light transmission
aggregometry of blood samples containing different doses of abciximab
using either ADP (
(
or collagen ( ) as an agonist (n = 4). c Platelet
coverage when blood samples containing different doses of the drug
abciximab were perfused through collagen-coated microfluidic devices
(n = 4). d Platelet coverage on the fixed endothelium pretreated with
TNF-α when blood samples from healthy donors versus subjects
treated with antiplatelet drugs were perfused through microfluidic
devices (n = 11). e Light transmission aggregometry of healthy versus
antiplatelet treated blood samples using ADP ( ) or collagen ( ) as
an agonist (n = 11). f Platelet coverage when healthy versus subject blood
samples were perfused through collagen-coated microfluidic devices
(n = 11). *P < 0.05
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diagnostics and advancing personalized medicine (Lian et al.
2010; Nelson and Terzic 2011). Importantly, given the small
size, simplicity and robustness of this microdevice, it also
could potentially be utilized for haemostasis and platelet func-
tion monitoring in point-of-care settings and for discovery of
new platelet modulators or anti-inflammatory drugs.
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